Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Biogen buys Nightstar in search of more eye gene therapies expanding into ophthalmology with rare retinal disease treatments
Two years after Biogen's $800M Nightstar acquisition, the lead choroideremia gene therapy missed primary and secondary endpoints in Phase 3, calling into…
Biogen gene therapy deal from Nightstar buyout has yet to bear fruit as clinical trials for choroideremia and retinitis pigmentosa disappoint
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Biogen agreed to acquire Nightstar Therapeutics for $25.50 per share in cash, ~$800M total. Adds two clinical-stage AAV-based gene therapies for inherited retinal disorders: NSR-REP1 for choroideremia and NSR-RPGR for X-linked retinitis pigmentosa. Closed June 7, 2019.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Biogen Inc. / Nightstar Therapeutics (this deal) | 2019 | $800M | — |
| Biogen Inc. / Reata Pharmaceuticals | 2023 | $7.3B | 73 |
| Biogen Inc. / Human Immunology Biosciences | 2024 | $1.1B | 68 |
| Biogen Inc. / RayThera Inc. | 2026 | $1.0B | 52 |
| Biogen Inc. / Bristol-Myers Squibb Company | 2017 | $710M | 15 |
| Biogen Inc. / TJ Biopharma Co., Ltd. | 2026 | $850M | — |
| Biogen Inc. / Vanqua Bio, Inc. | 2025 | $1.1B | — |
← Browse all deals · How we score deals
More: 2019 deals · Biogen Inc. deals · Ophthalmology deals